Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
18 Setembro 2023 - 9:00AM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced a collaboration with
Memorial Sloan Kettering Cancer Center (MSK) to study the use of
minimal residual disease (MRD) testing in breast cancer. The
research project will use Myriad’s MRD testing platform, a
tumor-informed high-definition assay that uses whole-genome
sequencing to achieve high sensitivity and specificity for
circulating tumor DNA (ctDNA).
Myriad is working together with Pedram Razavi, MD, PhD, a breast
medical oncologist and Director of Liquid Biopsy & Genomics at
MSK Global Biomarker Development Program. The MSK research team
will investigate the use of MRD testing for patients in two breast
cancer cohorts. The first will be in a metastatic patient
population treated with CDK4/6 inhibitors and will evaluate the
ability of MRD testing to predict treatment response. The second
will be focused on the neoadjuvant setting and will assess the
association of MRD testing with chemotherapy treatment
response.
“Several publications show that MRD testing provides prognostic
information about cancer recurrence, but the studies we are
undertaking with MSK will be among the first few to assess the
predictive benefit of MRD testing associated with particular
treatments,” said Dale Muzzey, chief scientific officer, Myriad
Genetics. “Because we use whole-genome sequencing to inform our MRD
assay, we often have thousands of tumor-specific sites to track
rather than the tens of sites available in other MRD assays. The
increased number of sites is particularly important in breast
cancer, which tends to have low tumor fraction, so having more
sites is critical to detecting low-level cancer with
confidence.”
“This collaboration could help to transform treatment for
patients with metastatic breast cancer by better determining who
will respond to a therapy and who will not,” said Dr. Razavi. “We
anticipate the MRD test from Myriad will be more sensitive and
specific than many other ctDNA offerings for monitoring the
response and, therefore, may more accurately identify the patients
who will or will not benefit from certain therapies. Importantly,
some of these patients may go undetected on a less-sensitive MRD
test. We are further excited by the prospect of using a combined
tumor tissue and ctDNA approach to predict and detect when and how
tumors acquire resistance, such that the therapeutic regimen can
adapt accordingly.”
Myriad’s MRD test is available for use in research studies
pursued jointly by Myriad and academic or pharmaceutical
investigators. It can be used to monitor ctDNA levels throughout a
cancer patient’s clinical care, starting immediately after
diagnosis and continuing through survivorship monitoring.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
the MSK research team will use the company’s high-definition MRD
testing platform and investigate the use of MRD testing for
patients in two breast cancer cohorts. These “forward-looking
statements” are management’s expectations of future events as of
the date hereof and are subject to known and unknown risks and
uncertainties that could cause actual results, conditions, and
events to differ materially and adversely from those anticipated.
Such factors include those risks described in the company’s filings
with the U.S. Securities and Exchange Commission, including the
company’s Annual Report on Form 10-K filed on March 1, 2023, as
well as any updates to those risk factors filed from time to time
in the company’s Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K. Myriad is not under any obligation, and it expressly
disclaims any obligation, to update or alter any forward-looking
statements, whether as a result of new information, future events
or otherwise except as required by law.
Media
Contact: |
Investor Contact: |
Glenn Farrell |
Matt Scalo |
(385) 318-3718 |
(801) 584-3532 |
PR@myriad.com |
IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024